Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.

IF 3
Qixiong Lin, Yanyan Wen, Yueyou Peng, Tianfeng Shi, Kunkun Liu, Qiufeng Yu, Wei Tian, Yanfeng Meng
{"title":"Cancer Cell-Coated PLGA Nanoparticles Loaded with Sorafenib and Spions for Hepatocellular Carcinoma Theranostics.","authors":"Qixiong Lin, Yanyan Wen, Yueyou Peng, Tianfeng Shi, Kunkun Liu, Qiufeng Yu, Wei Tian, Yanfeng Meng","doi":"10.2174/0115672018377065250717004240","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hepatocellular carcinoma (HCC) is the sixth most common malignant cancer worldwide, but the chemotherapy drugs used in the treatment of HCC patients have limited efficacy and cause severe side effects. To improve HCC treatment outcomes, a cancer cell membrane (CCM)-coated biomimetic nanodelivery system was designed to achieve enhanced anti-HCC effects.</p><p><strong>Methods: </strong>Poly (lactic-co-glycolic acid) (PLGA) was used to carry both sorafenib, which is used to treat advanced HCC, and superparamagnetic iron oxide nanoparticles (SPIONs). The prepared nanoparticles (NPs) were coated with Huh-7 cell membranes to obtain biomimetic nanoparticles (SFINPs@CCM). The physicochemical properties of SFINPS@CCM were then characterized, and the drug loading efficiency, release rate, transverse relaxation rate for MRI, fluorescence targeting ability, and anti-HCC ability were evaluated.</p><p><strong>Results: </strong>The SFINPS@CCM were successfully prepared. The loading efficiency of sorafenib in the SFINPs was 88.24%. The cumulative amount of sorafenib released from the SFINPs@CCM at 72 h was 72.96%. In vitro magnetic resonance imaging (MRI) showed the transverse relaxation rate was 25.448 mM-1 s-1. Meanwhile, the fluorescent tracing verified the homologous targeting ability of SFINPs@CCM to Huh-7 cells. The cytotoxicity of SFINPS@CCM was 29.48±5.74%, which was significantly higher than that of the SFINPs.</p><p><strong>Discussion: </strong>The study indicates that the SFINPs@CCM system achieves efficient drug delivery and enhances anti-HCC efficacy. While the results are encouraging, further research is needed to confirm broader applicability.</p><p><strong>Conclusion: </strong>The biomimetic nanodelivery system exhibits good targeting and excellent therapeutic effects, laying a technical foundation for preclinical studies.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672018377065250717004240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Hepatocellular carcinoma (HCC) is the sixth most common malignant cancer worldwide, but the chemotherapy drugs used in the treatment of HCC patients have limited efficacy and cause severe side effects. To improve HCC treatment outcomes, a cancer cell membrane (CCM)-coated biomimetic nanodelivery system was designed to achieve enhanced anti-HCC effects.

Methods: Poly (lactic-co-glycolic acid) (PLGA) was used to carry both sorafenib, which is used to treat advanced HCC, and superparamagnetic iron oxide nanoparticles (SPIONs). The prepared nanoparticles (NPs) were coated with Huh-7 cell membranes to obtain biomimetic nanoparticles (SFINPs@CCM). The physicochemical properties of SFINPS@CCM were then characterized, and the drug loading efficiency, release rate, transverse relaxation rate for MRI, fluorescence targeting ability, and anti-HCC ability were evaluated.

Results: The SFINPS@CCM were successfully prepared. The loading efficiency of sorafenib in the SFINPs was 88.24%. The cumulative amount of sorafenib released from the SFINPs@CCM at 72 h was 72.96%. In vitro magnetic resonance imaging (MRI) showed the transverse relaxation rate was 25.448 mM-1 s-1. Meanwhile, the fluorescent tracing verified the homologous targeting ability of SFINPs@CCM to Huh-7 cells. The cytotoxicity of SFINPS@CCM was 29.48±5.74%, which was significantly higher than that of the SFINPs.

Discussion: The study indicates that the SFINPs@CCM system achieves efficient drug delivery and enhances anti-HCC efficacy. While the results are encouraging, further research is needed to confirm broader applicability.

Conclusion: The biomimetic nanodelivery system exhibits good targeting and excellent therapeutic effects, laying a technical foundation for preclinical studies.

载索拉非尼和Spions的癌细胞包被PLGA纳米颗粒用于肝细胞癌治疗。
简介:肝细胞癌(HCC)是全球第六大常见恶性肿瘤,但用于治疗HCC患者的化疗药物疗效有限且副作用严重。为了提高HCC的治疗效果,设计了一种癌症细胞膜(CCM)涂层的仿生纳米递送系统来增强抗HCC的效果。方法:采用聚乳酸-羟基乙酸(PLGA)同时携带用于治疗晚期HCC的索拉非尼和超顺磁性氧化铁纳米颗粒(SPIONs)。将制备的纳米颗粒(NPs)包覆在Huh-7细胞膜上,获得仿生纳米颗粒(SFINPs@CCM)。表征SFINPS@CCM的理化性质,评价其载药效率、释放率、MRI横向松弛率、荧光靶向能力和抗hcc能力。结果:制备成功SFINPS@CCM。索拉非尼在SFINPs中的负载率为88.24%。72 h时SFINPs@CCM累计释放索拉非尼量为72.96%。体外磁共振成像(MRI)显示横向松弛速率为25.448 mM-1 s-1。同时,荧光示踪验证了SFINPs@CCM对Huh-7细胞的同源靶向能力。SFINPS@CCM的细胞毒性为29.48±5.74%,显著高于SFINPs。讨论:研究表明SFINPs@CCM系统实现了高效给药,提高了抗hcc的疗效。虽然结果令人鼓舞,但需要进一步的研究来证实其更广泛的适用性。结论:该仿生纳米递送系统具有良好的靶向性和良好的治疗效果,为临床前研究奠定了技术基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信